-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Glioblastoma is the most malignant glioma in astrocyte tumors.
tumors are located under the cortex and most grow throughout the upper brain hemisphere.
is immersive growth, often invades several brain lobes, and invades the deep structure, but also through the carcass spread to the opposite brain hemisphere.
glioblastoma growth speed, 70% to 80% of patients in 3 to 6 months, the course of the disease more than 1 year only 10%.
cytomegalovirus (CMV) antigens are present in glioblastomas, but do not exist in normal brain tissue, making them an ideal immunological target for the treatment of glioblastoma.
the study was a dose-increasing (4 dose level) type trial designed for Phase I.
first collected high-function autologous multi-clone CMV pp65-specific T cells in patients with glioblastoma, amplification in vitro, and transplanted back into the patient after 3 weeks of demotina (100 mg/m2) treatment.
6 Monday seaching courses for a total of 4 courses.
screened 65 patients, 41 cytomegalovirus seropositives, 25 were cetic cell isolation, and 20 completed at least one course of treatment. No dose-restrictive toxicity was observed
.
imaging completely alleviated 1 case, partial lysion 2 cases, median progression-free survival (PFS) 1.3 months (95% CI 0-8.3 months), 6 months PFS was 19% (95% CI, 7%-52%), and the median total survival period was 12 months (95% CI, 6 months - not up).
repeating INfusion cmV-T cells significantly increases the number of CMV-CD8T cells in the cycle, but inhibits the production of cytokines that suggest effect activity, especially T cells that come directly from glioblastoma.
Conclusion: CMV-specific T cells have good tolerance after filtering lymphocytes with large doses of lymphocytes.
but obviously, CMV seropositive does not guarantee that the tumor is sensitive to CMV-specific T cells, suggesting the heterogeneity of CMV antigen expression. In addition, the effect function of these T cells has decreased
, indicating that T-cells need to be further regulated to prevent dysfunction before large-scale clinical studies can be conducted.
.
